H3K9 histone methyltransferase G9a ameliorates dilated cardiomyopathy via the downregulation of cell adhesion molecules

Chen,Guiying; Wang,Xu; Zhang,Yina; Ru,Xiaoxue; Zhou,Lijun; Tian,Ye

doi:10.3892/mmr.2015.3218

H3K9 histone methyltransferase G9a ameliorates dilated cardiomyopathy via the downregulation of cell adhesion molecules

Authors:
- Guiying Chen
- Xu Wang
- Yina Zhang
- Xiaoxue Ru
- Lijun Zhou
- Ye Tian
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: January 19, 2015 https://doi.org/10.3892/mmr.2015.3218
Pages: 3872-3879

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dilated cardiomyopathy (DCM) is one of the leading causes of mortality; however, the underlying molecular mechanisms of DCM remain to be elucidated. H3K9 histone methyltransferase G9a has been previously characterized, although its functions in DCM are not yet understood. Cell adhesion molecules (CAM) are highly expressed in diseased human hearts and were thought to contribute to chronic degeneration in cardiac incompetence; however, it has been suggested that G9a may suppress the effects of CAM. The aim of the present study was to investigate whether G9a decreased the risk of DCM via regulation of CAM expression. A rat model of DCM was induced using furazolidone (FZ) treatment and numerous parameters were examined. G9a RNA interference (RNAi) was applied to primary neonatal cardiomyocytes (PNCs). Reverse transcription quantitative polymerase chain reaction and western blot analyses were used to examine the expression levels of G9a in the DCM model and PNCs. The growth rate of PNCs was evaluated following G9a RNAi and FZ treatment. The results confirmed that the expression levels of G9a were significantly decreased in the DCM model compared with those in the control group (P<0.01). Conversely, CAM expression levels were significantly increased in the DCM model compared with those in the control group (P<0.01). In PNCs, the expression of CAM was upregulated following G9a silencing using RNAi. Following three‑day culture, the growth rate of PNCs was inhibited by 70 and 35% following FZ treatment and G9a RNAi, respectively. In conclusion, G9a ameliorated DCM via downregulation of CAMs, therefore indicating its potential for use in the treatment of DCM.

View Figures

View References

1	Linke WA and Bücker S: King of hearts: a splicing factor rules cardiac proteins. Nat Med. 18:6602012. View Article : Google Scholar : PubMed/NCBI
2	Meyer L, Stubbs B, Fahrenbruch C, et al: Incidence, causes and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age a 30-year review. Circulation. 126:1363–1372. 2012. View Article : Google Scholar : PubMed/NCBI
3	Tachibana M, Sugimoto K, Fukushima T and Shinkai Y: Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem. 276:25309–25317. 2001. View Article : Google Scholar : PubMed/NCBI
4	Albert M and Peters AH: Genetic and epigenetic control of early mouse development. Curr Opin Genet Dev. 19:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
5	Feldman N, Gerson A, Fang J, et al: G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol. 8:188–194. 2006. View Article : Google Scholar : PubMed/NCBI
6	Chen MW, Hua KT, Kao HJ, et al: H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 70:7830–7840. 2010. View Article : Google Scholar : PubMed/NCBI
7	Devaux B, Scholz D, Hirche A, Klövekorn WP and Schaper J: Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J. 18:470–479. 1997. View Article : Google Scholar : PubMed/NCBI
8	Blankenberg S, Rupprecht HJ, Bickel C, et al: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 104:1336–1342. 2001. View Article : Google Scholar : PubMed/NCBI
9	Yin WH, Chen JW, Jen HL, et al: The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail. 5:507–516. 2003. View Article : Google Scholar : PubMed/NCBI
10	Noutsias M, Seeberg B, Schultheiss H-P and Kühl U: Expression of cell adhesion molecules in dilated cardiomyopathy evidence for endothelial activation in inflammatory cardiomyopathy. Circulation. 99:2124–2131. 1999. View Article : Google Scholar : PubMed/NCBI
11	Watanabe K, Ohta Y, Nakazawa M, et al: Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol. 130:1489–1495. 2000. View Article : Google Scholar : PubMed/NCBI
12	Chadfield MS and Hinton MH: In vitro activity of nitrofuran derivatives on growth and morphology of Salmonella enterica serotype enteritidis. J Appl Microbiol. 96:1002–1012. 2004. View Article : Google Scholar : PubMed/NCBI
13	Jankus E, Noren G and Staley N: Furazolidone-induced cardiac dilatation in turkeys. Avian Dis. 16:958–961. 1972. View Article : Google Scholar : PubMed/NCBI
14	Liao R, Nascimben L, Friedrich J, Gwathmey JK and Ingwall JS: Decreased energy reserve in an animal model of dilated cardiomyopathy relationship to contractile performance. Circ Res. 78:893–902. 1996. View Article : Google Scholar : PubMed/NCBI
15	Czarnecki CM: Animal models of drug-induced cardiomyopathy. Comp Biochem Physiol Part C. 79:9–14. 1984. View Article : Google Scholar
16	Huang RJ, Liu TW, Wu WF and Pang YS: Furazolidone induces dilated cardiomyopathy in rats [J]. Chinese J Pathophysiol. 11:2005.
17	Kubota T, McTiernan CF, Frye CS, et al: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res. 81:627–635. 1997. View Article : Google Scholar : PubMed/NCBI
18	Stein AB, Tiwari S, Thomas P, et al: Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res Cardiol. 102:28–41. 2007. View Article : Google Scholar
19	Delles M, Rengier F, Jeong YJ, et al: Estimation of aortic pressure waveforms from 4D phase-contrast MRI. Conf Proc IEEE Eng Med Biol Soc. 2013:731–734. 2013.PubMed/NCBI
20	Patel AR, Alsheikh-Ali AA, Mukherjee J, et al: 3D echocardiography to evaluate right atrial pressure in acutely decompensated heart failure correlation with invasive hemodynamics. JACC Cardiovasc Imaging. 4:938–945. 2011. View Article : Google Scholar : PubMed/NCBI
21	Goldberg MR, Tanaka W, Barchowsky A, et al: Effects of losartan on blood pressure, plasma renin activity and angiotensin II in volunteers. Hypertension. 21:704–713. 1993. View Article : Google Scholar : PubMed/NCBI
22	Kodish ME and Katz FH: Plasma renin concentration: comparison of angiotensinase inhibitors and correlation with plasma renin activity and aldosterone. J Lab Clin Med. 83:705–715. 1974.PubMed/NCBI
23	Takano S, Yoshitomi H, Togawa A, et al: Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene. 27:2810–2822. 2008. View Article : Google Scholar
24	Guo Z, Wang S, Jiao Q, Xu M and Gao F: RNAi targeting ryanodine receptor 2 protects rat cardiomyocytes from injury caused by simulated ischemia-reperfusion. Biomed Pharmacother. 64:184–190. 2010. View Article : Google Scholar : PubMed/NCBI
25	Carleton KL: Quantification of transcript levels with quantitative RT-PCR. Methods Mol Biol. 772:279–295. 2011. View Article : Google Scholar : PubMed/NCBI
26	Purcell NH, Tang G, Yu C, Mercurio F, DiDonato JA and Lin A: Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Nat Acad Sci USA. 98:6668–6673. 2001. View Article : Google Scholar : PubMed/NCBI
27	Moon C, Krawczyk M, Ahn D, et al: Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Nat Acad Sci. 100:11612–11617. 2003. View Article : Google Scholar : PubMed/NCBI
28	Paulus WJ, Tschöpe C, Sanderson JE, et al: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology. Eur Heart J. 28:2539–2550. 2007. View Article : Google Scholar : PubMed/NCBI
29	Avolio A: Central aortic blood pressure and cardiovascular risk a paradigm shift? Hypertension. 51:1470–1471. 2008. View Article : Google Scholar : PubMed/NCBI
30	Bombardini T, Cini D, Arpesella G and Picano E: WEB downloadable software for training in cardiovascular hemodynamics in the (3-D) stress echo lab. Cardiovasc Ultrasound. 8:482010. View Article : Google Scholar : PubMed/NCBI
31	Vander AJ: Control of renin release. Physiol Rev. 47:359–382. 1967.PubMed/NCBI
32	Gigante B, Rubattu S, Russo R, et al: Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Hypertension. 30(3 Pt 2): 563–568. 1997. View Article : Google Scholar : PubMed/NCBI
33	Sarafidis PA and Ruilope LM: Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int. 85:536–546. 2014. View Article : Google Scholar
34	Podwysocki B, Simon K and Gladysz A: Activity of angiotensin converting enzyme I and levels of acid alpha glycoprotein in selected liver and biliary tract diseases. Pol Tyg Lek. 48:268–270. 1993.(In Polish). PubMed/NCBI
35	Aoyagi T, Izumi Y, Hiroyama M, et al: Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 295:F100–F107. 2008. View Article : Google Scholar : PubMed/NCBI
36	Erdös EG and Skidgel RA: Renal metabolism of angiotensin I and II. Kidney Int Suppl. 30:S24–S27. 1990.PubMed/NCBI
37	Johnston CI: Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. J Hypertens. 10:S271992. View Article : Google Scholar
38	Ohtani K, Yutani C, Nagata S, Koretsune Y, Hori M and Kamada T: High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol. 25:1162–1169. 1995. View Article : Google Scholar : PubMed/NCBI
39	Zhang M, Shan H, Zhu Y-h, Lin L and Wei J: Attenuating effect of estrogen on furazolidone induced cardiomyocyte apoptosis is dependent on p66shc adapter protein. cardiology karger allschwilerstrasse 10, ch-4009 Basel, Switzerland: pp. 34. 2013
40	Genao A, Seth K, Schmidt U, Carles M and Gwathmey JK: Dilated cardiomyopathy in turkeys: an animal model for the study of human heart failure. Lab Anim Sci. 46:399–404. 1996.PubMed/NCBI
41	Tachibana M, Sugimoto K, Nozaki M, et al: G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16:1779–1791. 2002. View Article : Google Scholar : PubMed/NCBI
42	Roopra A, Qazi R, Schoenike B, Daley TJ and Morrison JF: Localized domains of G9a-mediated histone methylation are required for silencing of neuronal genes. Mol Cell. 14:727–738. 2004. View Article : Google Scholar : PubMed/NCBI
43	Hohl M, Wagner M, Reil JC, et al: HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest. 123:1359–1370. 2013. View Article : Google Scholar : PubMed/NCBI